- Home
- TLPH vs RDHL Comparison
TLPH vs RDHL Comparison
Compare TLPH & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- RDHL
- Stock Information
- Founded
- TLPH 2005
- RDHL 2009
- Country
- TLPH United States
- RDHL Israel
- Employees
- TLPH N/A
- RDHL N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- TLPH Health Care
- RDHL Health Care
- Exchange
- TLPH Nasdaq
- RDHL Nasdaq
- Market Cap
- TLPH 12.7M
- RDHL 8.6M
- IPO Year
- TLPH 2011
- RDHL N/A
- Fundamental
- Price
- TLPH $0.64
- RDHL $6.50
- Analyst Decision
- TLPH Strong Buy
- RDHL
- Analyst Count
- TLPH 2
- RDHL 0
- Target Price
- TLPH $4.50
- RDHL N/A
- AVG Volume (30 Days)
- TLPH 96.2K
- RDHL 21.6K
- Earning Date
- TLPH 11-13-2024
- RDHL 01-03-2025
- Dividend Yield
- TLPH N/A
- RDHL N/A
- EPS Growth
- TLPH N/A
- RDHL N/A
- EPS
- TLPH N/A
- RDHL N/A
- Revenue
- TLPH $281,000.00
- RDHL $3,707,000.00
- Revenue This Year
- TLPH N/A
- RDHL $224.90
- Revenue Next Year
- TLPH N/A
- RDHL $82.69
- P/E Ratio
- TLPH N/A
- RDHL N/A
- Revenue Growth
- TLPH N/A
- RDHL N/A
- 52 Week Low
- TLPH $0.60
- RDHL $6.00
- 52 Week High
- TLPH $1.61
- RDHL $40.50
- Technical
- Relative Strength Index (RSI)
- TLPH 39.75
- RDHL 38.21
- Support Level
- TLPH $0.60
- RDHL $6.00
- Resistance Level
- TLPH $0.76
- RDHL $7.30
- Average True Range (ATR)
- TLPH 0.07
- RDHL 0.51
- MACD
- TLPH -0.00
- RDHL -0.09
- Stochastic Oscillator
- TLPH 17.65
- RDHL 21.10
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.